The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
HOME > ARCHIVE
ARCHIVE
- FDA Not to Require PIII Data on Intranasal Granisetron: SNBL
June 20, 2011
- Daiichi Sankyo: Novel AD Treatment Memary Tablets
June 20, 2011
- Pfizer Japan Files Public Knowledge-based Application for Diflucan
June 20, 2011
- US CRO to Provide Financial Support to Codevelopment Partner of MediBIC
June 20, 2011
- Amgen to Focus on 4 Fields Including Cancer Taking Advantage of Its Strength in Biotech
June 20, 2011
- Novartis Files Public Knowledge-based Applications for Add'l Indications for 3 More Products
June 20, 2011
- Takeda Presents PI Data on MLN4924 at ASCO
June 20, 2011
- 9 Companies Inaugurate Japan CSO Association on June 1
June 13, 2011
- Trisenox Launched in South Korea through BL&H: Nippon Shinyaku
June 13, 2011
- Sanofi Pasteur to Develop Single-antigen IPV in Japan
June 13, 2011
- Eisai's Achievements Most Conspicuous in FY2011 Settlement of Accounts: Nomura Securities
June 13, 2011
- IMUC Becomes 18th Licensee for POTELLIGENT Technology: BioWa
June 13, 2011
- Kyowa Hakko Bio Establishes Efficient Amino Acid Derivative Manufacturing Process
June 13, 2011
- Teijin: Bonalon, Onealfa Contribute to Growth in Sales
June 13, 2011
- DSP to Inaugurate Global Oncology Business Development Office
June 13, 2011
- NanoCarrier's Micelle Technology Moves Closer to Patent in Japan
June 13, 2011
- Meiji HD: Pharmaceuticals Segment's Sales Up 2.3%
June 13, 2011
- JPMA to Issue Serious Warning against MSD over PC Violations
June 13, 2011
- OPC-34712's Promise as New Antipsychotic Confirmed in PII: Otsuka
June 13, 2011
- Yakult: Pharmaceutical Sales Up 10.8% Driven by Elplat
June 13, 2011
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…